PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: OmniActive Health Technolgies, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

OmniActives to Vigorously Press its Defenses Against Law Suit - OmniActive Health Technologies (OmniActives) will vigorously press its defenses at all appropriate legal platforms against a law suit filed by Kemin on July 17, 07 in the U.S. District Court for the Middle District of Florida, USA
OmniActives to Vigorously Press its Defenses Against Law Suit

 

NewswireToday - /newswire/ - Short Hills, NJ, United States, 2007/08/03 - OmniActive Health Technologies (OmniActives) will vigorously press its defenses at all appropriate legal platforms against a law suit filed by Kemin on July 17, 07 in the U.S. District Court for the Middle District of Florida, USA.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

“We have been aware of Kemin's 5,382,714 patent and previously considered the scope of protection afforded by this patent to ensure that our activities were well-clear of the patent. Having made deep investments in R&D, OmniActives respects intellectual property, and we have offered and sold our Lutemax® Free Lutein range in the industry with due diligence after ensuring uniqueness of our IP and patents. We believe that there is no merit to the contentions by Kemin. OmniActive’s Lutemax® Free Lutein product is covered by the 6,743,953 patent and other patent pending technologies, which describe a very different product and process than the 5,382,714 patent,” said Mr. Sanjaya Mariwala, Managing Director of OmniActive Health Technologies Pvt Ltd., Mumbai, India. “Our US subsidiary has just received a formal notice of the suit. Their complaint papers are being scrutinized by our legal team and attorneys,” he added.

OmniActives is the first and only company in the world with international patents for both Free Lutein (US Patent # 6,743,953) and Lutein Esters (US Patent # 6,737,535) to provide people across the world with nutritionally sound choices and formulators with the widest range of product options in the Lutein spectrum. In just three years, OmniActives has successfully innovated novel ingredients and technology solutions with validated and unique IP, delivering exceptional value to customers. OmniActives is extending technology and IP to related isomeric forms of lutein such as Zeaxanthin, and novel delivery platforms such as vegetarian and stabilized beadlets for lipophilic nutrients.

“We realize that the technological innovation and value that we have successfully brought to a stagnant and monopolistic Lutein market and to our customers, has been a powerful combination to cause disruptions in our competitors’ plans. With the inability to match up, litigation is not a surprising response we face from Kemin who has a well-known history of being litigious. In anticipation, we have been extremely diligent about our IP position. We will take all appropriate legal steps to demonstrate that Kemin’s contentions against OmniActives are based on a shaky foundation. It will only assure our partners that we will always bring products to the market that pass the stringent of tests in being unique IP protected inventions,” added Mr Mariwala.

OmniActives next-generation, patent pending beadletting technology was the first completely Vegetarian delivery system option for lutein and lutein esters where existing players only offered out-dated animal ingredient based beadlets to an increasingly diverse and safety conscious market. Customers have been delighted by how it has enabled them to better stabilize lutein in complex formulas without worrying about activity loss in manufacturing line or on the shelf. Particularly exciting have been the 5 times more potent 25% Lutein beadlets (in a market where 5-10 % versions are still the norm) to enable formulators to deliver to the consumer higher levels of lutein in keeping with emerging nutritional leads, without adding to the tablet or capsule size.

With a heritage of 135 years in the international food and nutrition business, the OmniActive’s Lutein range under the Lutemax® Free Lutein and Lutemax® Lutein Esters trade-mark set the trend for safe xanthophyll-based products for human food and nutrition applications by show-casing its own supply chain for Lutemax® products from seed to finished ingredient forms. Keeping in mind the end-use for human nutrition, OmniActives has completely eliminated the use of undesirable preservatives like ETQ, BHA, BHT, TBHQ, etc unlike many others in the marigold processing industry, and highlighted the need for GMO-free, trans-fat free ingredient systems. As a result, Lutemax® brand Free Lutein and Lutein Esters is now used in over 100 dietary supplements.

About OmniActives
OmniActive Health Technologies (omniactives.com) is promoted by Kancor Ingredients of India and is focused on innovating novel products and technologies for health and nutrition, building on Kancor’s 135 years history of developing and producing specialty extracts from plant origins.

OmniActives effectively uses Science and Technology to bring intelligent solutions that are patent protected, delivering exceptional value to pharmaceutical, nutritional and food companies.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: OmniActive Health Technolgies, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


OmniActives to Vigorously Press its Defenses Against Law Suit

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Hiren Doshi - OmniActive.com 
1-866-5883629 h.doshi[.]omniactives.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any OmniActive Health Technolgies, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From OmniActive Health Technolgies, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Deb Sheppard - Medium Psychic Author Speaker

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)